ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis"

  • Abstract Number: 1105 • ACR Convergence 2025

    Association between pre-existing rheumatoid arthritis and immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors

    Kevin Sheng-Kai Ma1, You Wu2, Rachael Stovall2, Jean Liew3 and Namrata Singh4, 1Center for Global Health, Perelman School of Medicine, Philadelphia, PA, 2University of Washington, Seattle, WA, 3Boston University, Boston, MA, 4University of Washington, Bellevue, WA

    Background/Purpose: Immune checkpoint inhibitors (ICIs), widely used to treat a variety of cancers, are associated with immune-related adverse events (irAEs) that are increasingly encountered in…
  • Abstract Number: 1031 • ACR Convergence 2025

    Trends and Gender Disparities in Rheumatoid Arthritis Burden in the United States: A Population-Based Time-Trend Analysis Using the Global Burden of Disease Database, 1990–2021

    Satani Sharkas1, Dina Murad2 and Dariush Jahandideh3, 1Boston Medical Center - Brighton, Brighton, MA, 2Tufts Medical Center, Boston, MA, 3Boston Medical Center - Brighton, Boston

    Background/Purpose: Rheumatoid arthritis (RA) is a growing public health concern in the United States, with increasing prevalence and disease burden over recent decades. This study…
  • Abstract Number: 0928 • ACR Convergence 2025

    Radiolabelled anti-citrullinated histone antibody CIT-013 as a tool to visualize NET rich inflamed joints in a collagen induced arthritic mouse model

    Annemarie Kip1, Daphne Dorst2, Birgitte Walgreen2, Monique Helsen2, Eric meldrum1, Renato Chirivi1 and Marije Koenders2, 1Citryll BV, Oss, Netherlands, 2RadboudUMC, Nijmegen, Netherlands

    Background/Purpose: Neutrophil Extracellular Traps (NETs) contribute to the pathophysiology of multiple immune-mediated inflammatory diseases including Rheumatoid Arthritis (RA), and may be promising therapeutic targets. The…
  • Abstract Number: 0835 • ACR Convergence 2025

    IgG Glycome In Early Rheumatoid Arthritis Differs From Matched Controls and Links Less Lean Mass to an Early Aging Phenotype

    Sidra Hashmi1, Brian Andonian2, Mary Ahern3, William Bennett4, Alyssa Sudnick5, Johanna Johnson5, Sridevi Krishnan3 and Kim Huffman5, 1Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, NC, USA, Morrisville, NC, 2Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, NC, USA, morrisville, 3University of Arizona, ARIZONA, 4Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, NC, USA, DURHAM, NC, 5Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, NC, USA, Durham

    Background/Purpose: Glycosylation is a post-translational enzymatic process important for protein function. Glycosylation patterns range from anti-inflammatory to inflammatory, and have been used to derive a…
  • Abstract Number: 0795 • ACR Convergence 2025

    Molecular Stratification of Rheumatoid Arthritis Patients by Multi-Omics Integration Reveals Disease Status and Predictors of Therapeutic Response

    Ismael Sanchez-Pareja1, Daniel Toro2, Carlos Pérez Sánchez3, Laura muñoz-Barrera1, Tomás Cerdó1, Elena Moreno-Caño4, Sagrario Corrales1, Lydia Formanti Alonso5, Rafaela Ortega-Castro6, Jerusalén Calvo5, Lourdes Ladehesa7, Concepción Aranda-Valera5, M Carmen Abalos-Aguilera8, Christian Merlo-Ruiz8, MARIA ANGELES AGUIRRE ZAMORANO1, Marta Alarcon-Riquelme9, Alejandro Escudero Contreras5 and Chary López pedrera10, 1Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, 2GENYO / Karolinska Institutet, Granada / Stockholm, Spain, 3Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/ CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, 4IMIBIC-Reina Sofia Hospital-University of Cordoba, Cordoba, Spain, Córdoba, Spain, 5IMIBIC / Reina Sofia Hospital / University of Cordoba, Córdoba, Spain, 6Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, 7IMIBIC-Reina Sofia Hospital-University of Cordoba, Cordoba, Spain, Cordoba, Spain, 8Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, 9Fundación Progreso y Salud, Andalusian Government, Granada, Spain, 10Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain

    Background/Purpose: To characterize molecular profiles of RA patients through multi-omics integration and evaluate their associations with disease status and therapeutic response to csDMARDs, TNF inhibitors…
  • Abstract Number: 0492 • ACR Convergence 2025

    Outcomes of Total Knee Replacement in Patients with Rheumatoid Arthritis: A National Inpatient Sample Database Analysis

    karun Shrestha1, Pravakar Parajuli2, Anil Regmi3, Prakriti Subedi4, Manoj Ghimire5, Sajana Poudel6, Mohammed Hasan7, Mahmoud Hashim8, Veera Durga Vaishnavi Kurra9 and ClementT Taoge10, 1Department of Internal Medicine, St. Barnabas Hospital, SBH Health System, Bronx, NY 10457, USA, BRONX, NY, 2Patan Academy of Health Sciences-School of Medicine (PAHS-SOM), Lalitpur, Bagmati, Nepal, 3Parkview Health, Fort Wayne, IN, 4St. Barnabas Hospital, Bronx, NY, 5St Barnabas Hospital, BRONX, NY, 6Cook County Health, CHICAGO, NY, 7Parkview Medical Center, Pueblo, CO, 8SBH Health System, New Rochelle, NY, 9University of Oklahoma Health Sciences Center, Oklahoma City, OK, 10Albert Einstein College of Medicine - Montefiore Medical Center, Bronx

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic, inflammatory disease of the joints with an estimated prevalence of 0.5% of people. Nearly 25% of RA patients…
  • Abstract Number: 0476 • ACR Convergence 2025

    Impact of Comorbidity Burden on the Efficacy of, a Direct Interleukin 6 Inhibitor, Olokizumab: Real World Evidence

    Maxim Korolev1, Alexander Dubikov2, Daria Bukhanova3, Alina Egorova3, Eugenyi Alekseev4, Sofia Kuzkina5 and Mikhail Samsonov3, 1Research Institute of Clinical and Experimental Lymрhology – Branch of the Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences, Novosibirsk, Russia, 2Rheumatology clinic of Professor Dubikov A.I., Vladivostok, Russia, 3R-Pharm JSC, Moscow, Russia, 4"R-Pharm", JSC, Moscow, Russia, 5R-Pharm, Moscow, Russia

    Background/Purpose: Comorbidities may affect the efficacy of bDMARDs in rheumatoid arthritis (RA). Post-hoc analysis of the randomized clinical trial (RCT) data shows that the efficacy…
  • Abstract Number: 0460 • ACR Convergence 2025

    The Impact of Early and Artificial Menopause on Dementia Risk Among Women with Rheumatoid Arthritis

    Ryan Salama1, Cassondra Hulshizer2, Cynthia Crowson3 and Elena myasoedova1, 1Mayo Clinic, Rochester, MN, 2Mayo Clinic, Rochester, 3Mayo Clinic, Stewartvillle, MN

    Background/Purpose: Alzheimer’s disease and related dementias present an increasing global health concern, with increasing incidence and prevalence. Hormonal fluctuations associated with menopause may exacerbate inflammatory…
  • Abstract Number: 0443 • ACR Convergence 2025

    Association between pan-immune-inflammation and synovitis as assessed by ultrasound in rheumatoid arthritis

    Elvira E Aguilar-Oliva1, Luis M Amezcua-Guerra2, ismael valenzuela3, Carina Soto-Fajardo4, Karina Arias5, Alejandra Espinosa6, Carlos Pineda4 and Luis H Silveira7, 1Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, TLALPAN, Distrito Federal, Mexico, 2Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, Mexico city, 3Instituto Nacional de Cardiología Ignacio Chávez, TLALPAN, Distrito Federal, Mexico, 4National Rehabilitation Institute " Luis Guillermo Ibarra Ibarra ", Mexico City, Mexico, 5Instituto Nacional de Rehabilitación Luis Guillermo Ibarra Ibarra, Tlalpan, Distrito Federal, Mexico, 6National Rehabilitation Institute " Luis Guillermo Ibarra Ibarra ", Ciudad de México, Mexico, 7Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, Mexico City, Mexico

    Background/Purpose: The pan-immune-inflammation value (PIV) is a novel composite biomarker derived from blood count parameters, reflecting the systemic balance of immune-inflammatory activity. Although it has…
  • Abstract Number: 0370 • ACR Convergence 2025

    Patient Preferences for Treatments of Rheumatoid Arthritis: A Discrete Choice Experiment Evaluating Preference for Advanced Drug Therapies and Neuroimmune Modulation Device

    Jeffrey Curtis1, Joshua Baker2, Shilpa Venkatachalam3, Sherry Danese4, Julie Ulloa5 and Ankit Shah6, 1University of Alabama at Birmingham, Birmingham, AL, 2University of Pennsylvania, Philadelphia, PA, 3Global Healthy Living Foundation, New York, NY, 4OutcomesInsights, Calabasas, CA, 5OutcomesInsights, Calabasas, 6SetPoint Medical, Valencia, CA

    Background/Purpose: Despite broadening treatment options for RA, several challenges and unmet needs remain. The 2021 ACR guideline for the treatment of RA marked a significant…
  • Abstract Number: 0210 • ACR Convergence 2025

    Improving Recombinant Zoster Vaccine Uptake in Younger Adults with Rheumatoid Arthritis through a Partnership with Specialty Pharmacy

    Akhil Sood1, Srijana Davuluri2, Sheila Haidar3, De Suan Huang3, April Ochoa3, Christy Bill1 and Janice Lin1, 1Stanford University, Palo Alto, CA, 2Stanford University, Stanford, CA, 3Stanford Health Care, Palo Alto, CA

    Background/Purpose: Despite guideline recommendations, recombinant zoster vaccine (RZV) uptake remains low among immunocompromised individuals younger than 50 years of age, notably those with rheumatoid arthritis…
  • Abstract Number: 0146 • ACR Convergence 2025

    Association between frailty and delirium and hospitalization outcomes among older adults with rheumatic diseases

    Bhavik Bansal1, Yehseo Jung2, Abdulla Damluji3, Parag Goyal4 and Namrata Singh5, 1UT Southwestern Medical Centre, Dallas, TX, 2University of Washington, Seattle, WA, 3Johns Hopkins, Baltimore, 4Weill Cornell, New York, 5University of Washington, Bellevue, WA

    Background/Purpose: We investigated the association of frailty and delirium, both independently and in combination, with in-hospital mortality and non-routine discharge (i.e. when a patient is…
  • Abstract Number: 0078 • ACR Convergence 2025

    Citrullinated Serum Albumin Is Not an Autoantigen in Rheumatoid Arthritis

    Farheen Sultan Shaikh, cecilia mustelin, Xiaoxing Wang and Tomas Mustelin, University of Washington, Seattle, WA

    Background/Purpose: Autoantibodies against citrullinated proteins (ACPAs) are diagnostic of rheumatoid arthritis (RA), an autoimmune disease primarily affecting synovial joints. Proteomic analyses have identified human serum…
  • Abstract Number: 0060 • ACR Convergence 2025

    Dietary Management of Rheumatoid Arthritis: A Functional Investigation of the Synbiotic Medical Food, SBD121

    Ryan Green1, Daniela Diaz-Infante Morales1, Alicia Ballok1, Kristine Kuhn2, Christopher Ritchlin3, Mark Charbonneau1, Eric Schott1 and Gerardo Toledo1, 1Solarea Bio Inc, Waltham, MA, 22022 - 2023 / Adult/ University of Colorado, Aurora, CO, 3University of Rochester Medical Center, Canandaigua, NY

    Background/Purpose: Rheumatoid arthritis (RA), affecting approximately 1% of the global population RA is a leading cause of disability worldwide. Despite available treatments, including methotrexate (MTX)…
  • Abstract Number: 2683 • ACR Convergence 2025

    Association of Genetic Risk for Pain Intensity with Longitudinal Disease Activity in Rheumatoid Arthritis

    Stevie Barry1, Katie McMenamin2, Austin Wheeler3, Bryant England3, Grant Cannon4, Brian Sauer5, Gary Kunkel6, Katherine Wysham7, Beth Wallace8, Andreas Reimold9, Gail Kerr10, Isaac Smith11, John Richards12, Iris Lee13, Rui Xiao1, Sylvanus Toikumo14, Henry Kranzler14, Rachel Kember14, Scott Damrauer14, Michael Levin14, Michael George1, Ted Mikuls3, Joshua Baker1 and Thomas Riley1, 1University of Pennsylvania, Philadelphia, PA, 2Boston Medical Center, Boston, MA, 3University of Nebraska Medical Center, Omaha, NE, 4University of Utah and Salt Lake City VA, Salt Lake City, UT, 5Salt Lake City VA/University of Utah, Salt Lake City, UT, 6University of Utah and George E Wahlen VAMC, Salt Lake City, UT, 7VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, 8Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, 9Dallas VA Medical Center, Dallas, TX, 10Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, 11Duke University Hospital, Durham, NC, 12Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, 13Washington University in St Louis, Saint Louis, MO, 14University of Pennsylvania / Corporal Michael J. Crescenz VAMC, Philadelphia, PA

    Background/Purpose: Guidelines recommend the use of composite scores to evaluate disease activity in RA and inform a treat-to-target approach. It is recognised that patient-reported components…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 219
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology